TheraRadar
← Back
Data updated: Mar 29, 2026

CHIESI

RespiratoryCardiovascularDermatology
Big Pharma

CHIESI is a major pharmaceutical company focused on Respiratory, Cardiovascular, Dermatology. Key products include KENGREAL.

1988
Since
15
Drugs
-
Trials
5
Approved (2yr)

Key Drugs

KENGREAL
cangrelor
Cardiovascular
P2Y12 2 indications · 2015
FILSUVEZ
birch triterpenes
1 indications · 2023
BETHKIS
tobramycin
Respiratory
1 indications · 2012
MYCAPSSA
octreotide acetate
Somatostatin receptor 1 indications · 2020

Top Drug Revenues Pro

Loading...

Revenue Over Time Pro

Loading...

Competitive Matchups Pro

Loading...

Recent Activity

FERRIPROX 2025-03-26
Labeling
FERRIPROX 2025-03-26
Labeling
FERRIPROX 2025-03-26
Labeling
CARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER 2025-02-21
Labeling
MYCAPSSA 2024-07-11
Labeling
SEC Filings Pro
Loading...

Therapeutic Areas

Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5

Respiratory 79%
1 drugs Phase 3: 16 Phase 2: 14 Phase 1: 26
Cardiovascular 18%
4 drugs Phase 3: 1
Dermatology 3%
0 drugs Phase 3: 1
Gastroenterology 1%
0 drugs Phase 1: 1

Pipeline Forecast

Loading...

Upcoming Trial Milestones Pro

Loading...

Patent Cliff Pro

Loading...

Competitors by Therapeutic Area

APOTHECON specialty
Dermatology, Cardiovascular, Gastroenterology, Respiratory
BAUSCH specialty
Dermatology, Cardiovascular, Gastroenterology
COREPHARMA other
Cardiovascular, Respiratory, Gastroenterology, Dermatology
Pfizer big-pharma
Dermatology, Gastroenterology
LEDERLE big-pharma
Cardiovascular, Dermatology, Respiratory